Novartis Announces Plan To Initiate Clinical Trial Of Canakinumab For Patients With COVID-19 Pneumonia
Novartis today announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing canakinumab, an interleukin (IL)-1β blocker, to treat a type of severe immune overreaction called cytokine release syndrome (CRS) in people with COVID-19 pneumonia. CRS could lead to life-threatening complications in patients with COVID-19.(1-3)
The study builds on early evidence from lab tests of COVID-19 patients who showed elevated IL-1β levels, among other cytokines.(2,4)
Novartis aims to rapidly enroll 450 patients at multiple medical centers across France, Germany, Italy, Spain, UK and the US and randomize them to receive either canakinumab or placebo on top of standard of care (SoC). The primary objective of the study is to demonstrate the benefit of canakinumab in combination with SoC in increasing the chance of survival without the need for invasive mechanical ventilation among patients with COVID-19 pneumonia. Top-line results are anticipated late summer 2020.
This trial initiation is part of the overall Novartis approach to applying our best science to tackling the issues related to COVID-19 and further underscores Novartis commitment to quickly deploy R&D resources, medicines, clinical expertise and philanthropic aid to combat COVID-19.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world.